Intravascular large B-cell lymphoma associated with myelofibrosis: A case report

JONG GWON CHOI¹, HWAN HWI CHO¹, SANG ROK KANG¹, SE MIN JANG², EUN HYUNG YOO³, HYUN JUNG CHO³, SUN MOON KIM⁴ and DO YEUN CHO¹

Departments of ¹Oncology-Hematology, ²Pathology, ³Laboratory Medicine and ⁴Gastroenterology, Konyang University Hospital, Daejeon 35365, Republic of Korea

Received November 9, 2016; Accepted March 14, 2017

DOI: 10.3892/mco.2017.1398

Abstract. Myelofibrosis (MF) is often accompanied by chronic myeloid leukemia, hairy cell leukemia, or certain primary myeloproliferative neoplasms, but is rarely associated with lymphoid neoplasms. We herein describe a case of intravascular large B-cell lymphoma (IVLBCl) with MF. IVLBCl is a rare, aggressive type of extranodal B-cell lymphoma, defined by proliferation of lymphomatous cells within small-to-medium-sized vessels. A 60-year-old woman was admitted to the hospital with anemia, thrombocytopenia and fever. Bone marrow biopsy findings included trilineage hematopoiesis, increased numbers of immature cells, markedly abnormal and enlarged megakaryocytes, and diffuse fibrosis in multiple focal areas throughout the entire bone marrow space. When the patient was first hospitalized, hepatosplenomegaly was not present. Although initially considered during differential diagnosis, an aggressive lymphoma could not be diagnosed prior to colonoscopy, which was conducted 4 weeks after admission. A biopsy of the terminal ileum revealed IVLBCl with cells with atypical nuclei. Immunophenotyping of the atypical large cells yielded a positive result for CD79a and negative results for terminal deoxynucleotidyl transferase, myeloperoxidase, CD3, CD10, CD20, B-cell lymphoma (Bcl)-2, Bcl-6 and cytomegalovirus. The patient was diagnosed with IVLBCl complicated by MF. This case may serve as a reminder that IVLBCl may be the cause of secondary MF.

Introduction

Intravascular large B-cell lymphoma (IVLBCl) is a rare type of extranodal diffuse large B-cell lymphoma (DLBCL) (1), which is characterized by the proliferation of lymphoma cells in the lumina of small vessels and capillaries, clinically aggressive behavior, usually with an unfavorable prognosis. In the majority of the cases, IVLBCl has extended to involve several regions at diagnosis. This disease was previously referred to as malignant angioendotheliomatosis; however, when the lymphoid origin of the malignant cells was identified, it was renamed intravascular malignant lymphomatosis (2,3). The precise mechanism underlying the distinctive behavior of this lymphoma remains unknown.

Although IVLBCl is typically associated with a rapid, aggressive course and short survival, a few exceptions of long-term survivors have been reported (4). The clinical manifestations of IVLBCl are diverse, as the majority of signs and symptoms are related to the organ most extensively affected. Furthermore, clinical differences may vary according to the geographical origin of the patients (5). Patients with IVLBCl in Western countries are usually predisposed to a high frequency of central nervous system and skin involvement, whereas Asian patients exhibit a tendency towards bone marrow involvement, thrombocytopenia, fever and haemophagocytic syndrome; however, these different clinical patterns do not affect patient survival. Variation in other clinical parameters does not affect prognosis, except for presence of the cutaneous variant, which is associated with a better prognosis. However, the cutaneous variant of IVLBCl is very rare in Asia (3%) compared with Western countries (24%), and patients with this variant present with particular clinical characteristics (6).

Laboratory findings are not usually specific, but may raise suspicion regarding a diagnosis of IVLBCl. Approximately 65% of patients with IVLBCl have anemia. Furthermore, an increase in serum lactate dehydrogenase (LDH) and β2-microglobulin levels is observed in ≥80% of the patients. Monoclonal gamopathy is reported in 14% of the patients and hepatic, renal, or thyroid function is affected in 15-20% of the patients. Therefore, such tests are generally used in the staging workup for IVLBCl. The conventional staging system frequently leads to a high proportion of false negatives when using various imaging methods, such as whole-body computed tomography. This may be due to the fact that IVLBCl mainly occurs without identifiable tumor masses or lymphadenopathy (5,6).

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by the accumulation of reticulin and
collagen fibers, as well as the proliferation of fibroblastic mesenchymal cells in the bone marrow. These changes are associated with increases in neangiogenesis and circulating levels of particular cytokines, including transforming growth factor (TGF)-β1, platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF)-β (7). MF may be classified as primary idiopathic or secondary type at the onset or during the course of the disease. Secondary MF is commonly observed in acute megaloblastic leukemia, chronic myeloid leukemia, hairy cell leukemia and myelodysplastic syndrome. However, secondary MF is rare in malignant lymphoma.

We herein report a case of IVLBCL associated with MF, which improved following chemotherapy for the lymphoma.

Case report

A 60-year-old woman presented at the Konyang University Hospital (Daejeon, South Korea) on March 10, 2016, with fever that started 1 month prior and thrombocytopenia identified at a local clinic. At the time of admission, the patient had a blood pressure of 120/70 mmHg, a heart rate of 88 beats per min, a respiratory rate of 20 breaths per min and a temperature of 39˚C. There was no significant previous medical history of hypertension, diabetes mellitus, or tuberculosis. On physical examination, multiple ecchymoses were observed over the lower extremities bilaterally, with dried blood in the pharynx and gums and edema of the lower lip. However, there was no enlargement of cervical or inguinal lymph nodes. The patient’s abdomen was mildly distended but soft, non-tender, without enlarged organs or palpable masses. The results of other examinations were unremarkable.

The laboratory tests revealed a white blood cell (WBC) count of 6,900/µl, a hemoglobin level of 7.3 g/dl and a platelet count of 26,000/µl. The WBCs comprised 55% segmented neutrophils, 27% lymphocytes, 12% monocytes, 1% eosinophils and 1% basophils. The reticulocyte count was within the normal range. Leukemic blasts were not observed. Coagulation tests revealed a prothrombin time of 14.8 sec and an activated partial thromboplastin time of 32.3 sec. The fibrinogen level was 350 mg/dl, the D-dimer value was 2.1 µg/ml and the antithrombin activity 72% (not suggestive of disseminated intravascular coagulation). Peripheral blood examination revealed normocytic and normochromic red blood cells, no polychromasia, a normal WBC count with no toxic granulations or vacuolations, and a decreased platelet count. The serum LDH level was 832 U/l (normal range, 120-240 U/l). The total bilirubin level was 1.04 mg/dl. The results of other blood tests, including creatinine and bicarbonate, and liver function tests were unremarkable. In immunoassay tests, the patient tested negative for antibodies against Hantaan virus, rickettsia, leptospiira, scrub typhus and severe fever with thrombocytopenia syndrome virus. The differential diagnosis also included fulminant infection or autoimmune disease, which were excluded by laboratory and microbial examinations.

On computed tomography (CT) examination, the liver, pancreas, spleen and kidneys were normal. The presence of thoracic or abdominal involvement was excluded. Bone marrow examination using pelvic trephine biopsy and aspiration resulted in ‘dry tap’. Bone marrow aspiration slides revealed no particles or peripheral dilution, and immature

Figure 1. Bone marrow aspirate showing a lack of particles and peripheral dilution. Immature cells were occasionally identified (Wright-Giemsa staining; magnification, x200).

Figure 2. (A) Trephine bone marrow biopsy showing ~60% cellularity, with increased atypical megakaryocytes and fibrosis (hematoxylin and eosin staining; magnification, x200). (B) Reticulin staining of bone marrow biopsy revealed grade 3 reticulin fibrosis (reticulin staining; original magnification, x400).

Figure 3. Integrated ¹⁸F-Fluorodeoxyglucose positron emission tomography-computed tomography revealed focal hypermetabolism in the terminal ileum [maximum standardized uptake value (SUV_max)=5.9; delayed SUV_max=7.8].
cells were occasionally identified (Fig. 1). Bone marrow biopsy showed an estimated cellularity of ~60%, which was considered mildly hypercellular for the patient’s age. In cellular areas, trilineage hematopoiesis was observed, along with increased numbers of immature cells. There were increased numbers of megakaryocytes, which were markedly abnormal, with various shapes and increased size. There was deviation from the normal nuclear: Cytoplasmic ratio and an abnormal pattern of chromatin. Diffuse fibrosis was observed in multiple focal areas throughout the bone marrow space (Fig. 2). The pathological diagnosis from bone marrow biopsy recommended excluding post-essential thrombocythemia MF. Furthermore, JAK2 V617F mutation and immunoglobulin gene rearrangement were not detected.

Although the patient had been treated with antibiotics, she had recurrent fever. Blood and urine cultures were negative. An integrated $^{18}$F-fluorodeoxyglucose positron emission tomography/CT scan of the skull to mid-thigh revealed an enlarged and hypermetabolic terminal ileum, with a maximum standardized uptake value of 7.2 (Fig. 3). Subsequently, the patient underwent total colonoscopy; this examination ruled out ulcerative colitis or tuberculous colitis of the terminal ileum (Fig. 4). On microscopic examination of the terminal ileum, the mucosal architecture was relatively well-preserved. However, there were numerous lymphoid cells present in the lumina of small blood vessels. The lymphoid cells in the small vessels of the mucosa included large cells with atypical nuclei and prominent nucleoli, and occasional mitotic figures. The cells were solely lodged in the lumina of the vessels and absent from the lamina propria. Immunohistochemical analysis revealed that the large cells were positive for CD79a, but negative for CD20, terminal deoxynucleotidyl transferase and myeloperoxidase. The histopathological findings suggested the diagnosis of IVLBCL (Fig. 5).

Two days after receiving the pathology report from the colonoscopic biopsy, the patient abruptly developed hyperbilirubinemia (peak total bilirubin, 16.5 mg/dl). A CT scan revealed hepatomegaly and an enlarged spleen, and advancing...
transmural thickening of the wall of the terminal ileum due to the lymphoma.

Based on the clinical findings, the patient was diagnosed with an IVLBCL with MF. The lymphoma was classified as clinical stage IV. Subsequently, the patient underwent chemotherapy with cyclophosphamide 1,250 mg, day 1; doxorubicin 83 mg, day 1; vincristine 2 mg, day 1; and prednisone 100 mg, days 1-5 (CHOP regimen). The B symptoms resolved, with additional resolution of hyperbilirubinemia and a reduction in the size of the liver. However, the patient developed drowsiness 7 days after the first cycle of chemotherapy, as well as pneumonia with pancytopenia. Granulocyte colony-stimulating factor and intravenous antibiotic injections were administered; however, the patient succumbed to the disease 15 days after the first cycle of chemotherapy.

Discussion

Chronic idiopathic MF, also referred to as MF, may be described as a disorder of myeloepoietic tissue relating to abnormal cloning of hematopoietic stem cells in the bone marrow accompanied by fibrosis (replacement of cells in the marrow with scar tissue), which impairs the production of normal blood cells (8). MF is often accompanied by an enlarged spleen and/or liver, inadequate numbers of platelets, gout and high uric acid levels. Secondary MF is observed in association with various systemic diseases, including metastatic carcinoma, tuberculosis, osteoporosis and toxic marrow injury following chemical exposure or irradiation (9,10). Secondary MF may also occur in various hematological diseases, such as myelodysplastic syndrome, hairy cell leukemia, chronic myeloid leukemia and acute megakaryoblastic leukemia (11). However, secondary MF is rare in malignant lymphoma and cases of MF associated with IVLBCL are extremely scarce.

IVLBCL is an aggressive, rare extranodal lymphoma that is characterized by the localization of lymphomatous cells in small- to medium-sized vessels; it is also recognized as a subset of DLBCL in the 2008 WHO classification (12).

IVLBCL may affect any organ and it is likely to have already spread widely at the time of diagnosis. Various symptoms and signs may appear, depending on its distribution. These may be either non-specific and generalized (e.g., B symptoms, elevated LDH level and cytopenia) or confined to the affected organ (e.g., cutaneous lesions or hepatic insufficiency). This variation leads to a significant range of differential diagnoses, including neoplastic, infectious and autoimmune disorders.

The lack of lymph node involvement and mass lesions further confounds the clinical picture and delays diagnosis. Generally, the lymphoma cells are large with round, readily distinguishable nuclei. Furthermore, mitotic activity is high. However, rare cases with smaller cells or anaplastic morphology have been reported.

IVLBCL may also involve the sinusoidal spaces of the bone marrow, liver and spleen. This predilection for vascular spaces has been hypothesized to be secondary to a defect in homing receptors on cells, such as a lack of CD29 (β1-integrin) and CD54 (intercellular adhesion molecule-1) adhesion molecules (13). In particular, involvement of the bone marrow may be difficult to detect, as the neoplastic cells are diffuse rather than aggregated, and their morphology may mimic that of hematopoietic precursors, as seen in the case presented herein. Malignant cells uniformly express pan-B-cell antigens (CD20, CD79a) and may also express other antigens, such as CD5 (38%) and CD10 (13%).

Little is known on the correlation between MF and lymphoma, except for information provided by the few reported cases of MF with concomitant or subsequent lymphoma (14). Although lymphoma is a well-known cause of MF, it is uncommon. Gisselbrecht et al reported no patients with MF in a series of 1,883 patients with diffuse aggressive non-Hodgkin lymphoma (15). In addition, the pathogenesis of the fibrotic changes in the bone marrow of patients with IVLBCL was unknown until recently. In the majority of MF cases, megakaryocytes with multilobulated nuclei proliferate and exhibit clustering in the marrow (16). These megakaryocytes have abnormally located P-selectin in their intracytoplasmic vacuoles and demarcation membrane system, leading to increased emperiploïdes of neutrophils (17). Neutrophils release enzymes that cause megakaryocytes to secrete various cytokines, including TGF-β, PDGF and FGF, from their α-granules (18). These cytokines play an essential role in the development of stromal proliferation. PDGF induces fibroblast proliferation, while TGF-β promotes synthesis and accumulation of extracellular matrix proteins, including fibronectin, type I and III collagens, and endothelial cells, causing neoangiogenesis (19,20). Production of osteoprotegerin by stromal and endothelial cells leads to unbalanced osteoblast proliferation, resulting in osteosclerosis and neoangiogenesis (21). Therefore, MF is considered to be a clonal disorder of a hematopoietic stem cell and fibrosis is considered to be a secondary change caused by the release of cytokines from progenitor cells (22).

In cases of lymphoma with secondary MF, PDGF is mostly synthesized in megakaryocytes, but may also be secreted by cells of the monococyte-macrophage lineage (23). Furthermore, T cells secrete TGF, which may cause fibrosis. The plasma TGF-β levels were found to be elevated in cases of MF associated with peripheral T-cell, cytotoxic T-cell and splenic marginal zone lymphomas (24-27). TGF-β was elevated prior to treatment in a patient with DLBCL and significantly decreased following treatment, and was associated with advanced stage, a high-risk international prognostic index and bulky disease (28). Furthermore, Munoz et al reported overexpression of Smad1 in lymphoma cells, and phosphorylation of Smad1 is mediated by TGF-β1 in the microenvironment of lymphoma cells; they found that activation of Smad1 by TGF-β1 induced non-Hodgkin lymphoma cell proliferation (29). The findings presented herein suggest that DLBCL cells produce cytokines, such as PDGF and TGF-β, which cause their morphological change into spindle-shaped cells.

The case presented herein highlights several pitfalls in the recognition and diagnosis of IVLBCL. The major symptoms were non-specific: Fever of unknown origin, multilineage cytopenia and hepatosplenomegaly. Although bone marrow biopsy was initially performed, the burden of disease at that time was low and the morphology was ambiguous. Therefore, certain characteristics led to misdiagnosis as primary MF. When the disease eventually caused severe hepatomegaly and hyperbilirubinemia, the lymphoma cells were present in
greater numbers and were clearly recognizable as lymphoma-
tous, particularly in the liver, but less so in the marrow. Of
note, although hepatomegaly and hyperbilirubinemia were
considered to be due to the IVLBCL infiltration of the liver,
this was not proven pathologically. However, these manifes-
tations improved following the initiation of chemotherapy,
despite the delay in diagnosis.

In the present case, the patient developed MF and IVLBCL
simultaneously, and these were treated with chemotherapy.
The presentation of MF was similar to that of IVLBCL, suggest-
ing that IVLBCL plays an important role in the pathogenesis of MF.
Certain cytokines are hypothesized to stimulate the growth of
fibroblasts and the synthesis of collagen by bone marrow fibro-
blasts. Further studies and additional case reports are required
to elucidate the pathogenesis of secondary MF and improve
our understanding of the immunological dysregulation associ-
ated with IVLBCL. A search for lymphoid malignancy should
be considered when the cause of MF is unclear.

References

1. Gatter KC and Warnke RA: Intravascular large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H and Vardiman JW (eds): World
Health Organization Classification of Tumours: Pathology and
Genetics of Haematopoietic and Lymphoid Tissues. International
Agency for Research on Cancer (IARC), Lyon, IARC Press, pages pp177-178, 1991.

2. Sepp N, Schuler G, Romani N, Geissler D, Gattringer C, Burg G, Bartram CR and Fritsch P: Intravascular lymphomatosis (angioendotheliomatosis): Evidence for a T-cell origin in two
 cases. Hum Pathol 21: 1051-1056, 1990.

3. Shieh K, Battifora H, Winberg CD, Burke JS, Ben-Ezra J, Ellinger GM, Quigley NJ, Fernandez BB, Morrow D and Rappaport H: Further evidence that ‘malignant angioendo-
theliatomatosis’ is an angiotropic large-cell lymphoma. N Engl J Med 314: 943-948, 1986.

4. Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosi E, Zucca E, Rossi G, Lopez-Guillermo A, Pavlovsky MA, et al. Intravascular lymphoma: Clinical presen-
tation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous
variant’. Br J Haematol 127: 173-183, 2004.

5. Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamura J, Kojima M, Miura I, Mori N, Yoshino T and Nakamura S: Intravascular large B-cell lymphoma (IVLBCL): A clinicopathological study of 96 cases with special reference to the immunophenotypic heterogeneity of CDS. Blood 109: 478-485, 2007.

6. Murase T, Nakamura S, Kawachi K, Matsuzaki H, Sakai C, Inaba T, Nasu K, Tashiro K, Suchi T and Saito H: An Asian variant of intravascular large B-cell lymphoma: Clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 111: 826-834, 2000.

7. Rameshwar P, Oh HS, Yook C, Gascon P and Chang VT: Substance p-fibroblast-cytokine interactions in myeloprolif-
erative disorders with bone marrow fibrosis. Acta Haematol 109: 1-10, 2003.

8. Tefferi A: Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89: 915-925, 2014.

9. Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P and Pellegrin JL: Reversible myelofibrosis induced by tuberculosis. Clin Infect Dis 34: 1641-1643, 2002.

10. Atasever T, Vural G, Yenidunya S, Ataoglu O, Atacel V and Unlü M: Tc-99mMIBI bone marrow uptake in bone marrow fibrosis secondary to metastatic breast carcinoma. Clin Nucl Med 22: 655-656, 1997.

11. Fu R, Yu H, Wu YH, Liu H and Shao ZH: Hodgkin's lymphoma associated with myelofibrosis: A case report. Oncol Lett 10: 1551-1554, 2015.